Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 142

1.

Early Alpha-Fetoprotein Response Associated with Treatment Efficacy of Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.

Shao YY, Liu TH, Hsu C, Lu LC, Shen YC, Lin ZZ, Cheng AL, Hsu CH.

Liver Int. 2019 Aug 10. doi: 10.1111/liv.14210. [Epub ahead of print]

PMID:
31400295
2.

PTEN Methylation by NSD2 Controls Cellular Sensitivity to DNA Damage.

Zhang J, Lee YR, Dang F, Gan W, Menon AV, Katon JM, Hsu CH, Asara JM, Tibarewal P, Leslie NR, Shi Y, Pandolfi PP, Wei W.

Cancer Discov. 2019 Jun 19. doi: 10.1158/2159-8290.CD-18-0083. [Epub ahead of print]

PMID:
31217297
3.

Considerations of heterogeneity in clinical trials for hepatocellular carcinoma.

Liu TH, Shao YY, Lu LC, Shen YC, Hsu C, Lin ZZ, Hsu CH, Cheng AL.

Expert Rev Gastroenterol Hepatol. 2019 Jul;13(7):615-621. doi: 10.1080/17474124.2019.1621165. Epub 2019 May 27.

PMID:
31132887
4.

Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives.

Lu LC, Chang CJ, Hsu CH.

J Hepatocell Carcinoma. 2019 May 7;6:71-84. doi: 10.2147/JHC.S159693. eCollection 2019. Review.

5.

Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway.

Lee YR, Chen M, Lee JD, Zhang J, Lin SY, Fu TM, Chen H, Ishikawa T, Chiang SY, Katon J, Zhang Y, Shulga YV, Bester AC, Fung J, Monteleone E, Wan L, Shen C, Hsu CH, Papa A, Clohessy JG, Teruya-Feldstein J, Jain S, Wu H, Matesic L, Chen RH, Wei W, Pandolfi PP.

Science. 2019 May 17;364(6441). pii: eaau0159. doi: 10.1126/science.aau0159.

PMID:
31097636
6.

Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment.

Lu LC, Lee YH, Chang CJ, Shun CT, Fang CY, Shao YY, Liu TH, Cheng AL, Hsu CH.

Liver Cancer. 2019 Mar;8(2):110-120. doi: 10.1159/000489021. Epub 2018 Jun 15.

7.

Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment.

Lu SL, Hsu FM, Tsai CL, Lee JM, Huang PM, Hsu CH, Lin CC, Chang YL, Hsieh MS, Cheng JC.

Eur J Surg Oncol. 2019 Aug;45(8):1498-1504. doi: 10.1016/j.ejso.2019.03.020. Epub 2019 Mar 19.

PMID:
30910457
8.

A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors.

Lee JH, Chen TW, Hsu CH, Yen YH, Yang JC, Cheng AL, Sasaki SI, Chiu LL, Sugihara M, Ishizuka T, Oguma T, Tajima N, Lin CC.

Invest New Drugs. 2019 Mar 2. doi: 10.1007/s10637-019-00745-z. [Epub ahead of print]

PMID:
30825104
9.

Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma.

Huang TC, Lin CC, Wu YC, Chia-Hsien Cheng J, Lee JM, Wang HP, Huang PM, Hsu FM, Yeh KH, Cheng AL, Tzen KY, Hsu CH.

J Formos Med Assoc. 2019 Jun;118(6):1024-1030. doi: 10.1016/j.jfma.2018.11.003. Epub 2018 Nov 28.

10.

Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver Failure.

Liu TH, Hsu CH, Shao YY.

Liver Cancer. 2018 May;7(2):205-208. doi: 10.1159/000486763. Epub 2018 Apr 20. No abstract available.

11.

Number of Resected Lymph Nodes and Survival of Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Preoperative Chemoradiotherapy.

Guo JC, Lin CC, Huang TC, Huang PM, Kuo HY, Chang CH, Wang CC, Cheng JC, Yeh KH, Hsu CH, Lee JM.

Anticancer Res. 2018 Mar;38(3):1569-1577.

PMID:
29491087
12.

Response to Nivolumab as Salvage Therapy in a Patient with Thymic Carcinoma.

Yang PC, Guo JC, Hsieh MS, Lin CC, Hsu CH.

J Thorac Oncol. 2018 Mar;13(3):e36-e39. doi: 10.1016/j.jtho.2017.10.022. No abstract available.

13.
14.

Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma.

Chang CJ, Yang YH, Chiu CJ, Lu LC, Liao CC, Liang CW, Hsu CH, Cheng AL.

Int J Cancer. 2018 May 1;142(9):1878-1889. doi: 10.1002/ijc.31216. Epub 2017 Dec 26.

15.

Corrigendum: RNA m6A methylation regulates the ultraviolet-induced DNA damage response.

Xiang Y, Laurent B, Hsu CH, Nachtergaele S, Lu Z, Sheng W, Xu C, Chen H, Ouyang J, Wang S, Ling D, Hsu PH, Zou L, Jambhekar A, He C, Shi Y.

Nature. 2017 Dec 21;552(7685):430. doi: 10.1038/nature24007. Epub 2017 Nov 29.

PMID:
29186122
16.

Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells.

Shao YY, Hsieh MS, Wang HY, Li YS, Lin H, Hsu HW, Huang CY, Hsu CH, Cheng AL.

Oncotarget. 2017 Sep 30;8(49):86681-86692. doi: 10.18632/oncotarget.21407. eCollection 2017 Oct 17.

17.

High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma.

Shao YY, Lin H, Li YS, Lee YH, Chen HM, Cheng AL, Hsu CH.

Jpn J Clin Oncol. 2017 Oct 1;47(10):949-953. doi: 10.1093/jjco/hyx103.

PMID:
28981732
18.

Musashi-1 Enhances Glioblastoma Cell Migration and Cytoskeletal Dynamics through Translational Inhibition of Tensin3.

Chen HY, Lin LT, Wang ML, Laurent B, Hsu CH, Pan CM, Jiang WR, Chen PY, Ma HI, Chen YW, Huang PI, Chiou A, Chiou SH.

Sci Rep. 2017 Aug 18;7(1):8710. doi: 10.1038/s41598-017-09504-7.

19.

Right or left? Side selection for a totally implantable vascular access device: a randomised observational study.

Lin WY, Lin CP, Hsu CH, Lee YH, Lin YT, Hsu MC, Shao YY.

Br J Cancer. 2017 Sep 26;117(7):932-937. doi: 10.1038/bjc.2017.264. Epub 2017 Aug 8.

20.

Dynamic Contrast-enhanced MR Imaging of Advanced Hepatocellular Carcinoma: Comparison with the Liver Parenchyma and Correlation with the Survival of Patients Receiving Systemic Therapy.

Chen BB, Hsu CY, Yu CW, Liang PC, Hsu C, Hsu CH, Cheng AL, Ting-Fang Shih T.

Radiology. 2017 Jun;283(3):923. doi: 10.1148/radiol.2017174012. No abstract available.

PMID:
28514212

Supplemental Content

Loading ...
Support Center